Introduction: Candidacy for deep brain stimulation (DBS) in Parkinson disease (PD) is typically assessed by the preoperative motor response to levodopa along with an interdisciplinary evaluation. However, recent cases treated at our institution have achieved good outcomes with DBS despite a sub-30% improvement in motor scores. The aim of this study was to examine the outcomes of DBS in a subset of patients who failed to reach the 30% motor improvement threshold.
D eep brain stimulation (DBS) is commonly employed for the treatment of medication-refractory symptoms in Parkinson disease (PD). Recent studies have revealed the efficacy of DBS for both subthalamic nucleus (STN) and globus pallidus interna (GPi) targets in well-selected patients. [1] [2] [3] [4] [5] [6] [7] Institutions with expertise in DBS commonly employ neurocognitive and psychiatric testing along with a levodopa/ dopaminergic challenge test to screen potential candidates. In the latter, potential DBS candidates report to their neurologist's office 12 hours off their dopaminergic medications, and are then evaluated with the Unified Parkinson Disease Rating Scale (UPDRS) in the "off" state. Afterwards, they are challenged with a suprathreshold dose of dopaminergic medication and reevaluated at their best "on" state. Optimal surgical candidates typically demonstrate at least a 30% improvement in the motor portion (Part III) of the UPDRS, 4, [8] [9] [10] [11] [12] as levodopa response has been considered to be one of the strongest indicators of a positive outcome in DBS for PD. 8, 9, 12 There may, however, be patients who do not achieve a 30% improvement with levodopa or dopaminergic medications but have alternative and potentially responsive indications for DBS (dyskinesia, "on/off" motor fluctuation, and medication-refractory tremor). 12 The aim of this study was to examine alternative indications and the surgical outcomes of a tailored unilateral DBS approach for a cohort of PD patients with a sub-30% improvement on a levodopa/dopaminergic challenge test. After patients were identified, retrospective chart reviews were performed and history, performance scores, operative information, and other information were obtained for each patient. A levodopa/dopaminergic challenge test was performed on all potential DBS candidates, and definitive diagnosis of PD was confirmed by a movement disorders fellowship trained specialist at our institution. Patients reported to the clinic after being "off" levodopa/dopaminergic therapy for a minimum of 12 hours. A suprathreshold dose of their usual PD medications (1.5 times the dose) was then administered. The UPDRS Part III was collected in the "off" and then "on" medication states and the percentage improvement noted. Patients with dose failures, 45 minutes after ingesting dopaminergics received an additional dose of carbidopa/levodopa 25/100 mg, in an attempt to document the best "on" response. Patients with a sub-30% improvement, but with disabling dyskinesia, "on/off" motor fluctuations, or medication-refractory tremor resulting in subjective impairment in quality of life (QOL) were further considered for DBS by our interdisciplinary DBS team (neurologist, neurosurgeon, neuropsychologist, psychiatrist). In addition, previous history of successful lesional surgery (eg, pallidotomy) was also considered as an indication for DBS despite a sub-30% response. Excluded were patients with a sub-30% improvement on a levodopa/dopaminergic challenge test without disabling tremor, dyskinesia, and/or on-off fluctuations. We did not specifically track those excluded.
METHODS

Study Design
Performance Testing
UPDRS Part III (motor) scores were obtained preoperatively in both "on" and "off" dopaminergic states and then repeated at 4 months, 1 year, and last follow-up in an "off medication/on DBS" state. In addition, the UPDRS Part II (activities of daily living), Part IV (motor fluctuations and dyskinesia), and dyskinesia rating scale contralateral to the side of DBS implantation were documented (range 0 to 5 with 5 being the worst). 13 Parkinson disease questionnaire (PDQ-39) QOL scores were also assessed at baseline and at 6 months and last follow-up. The PDQ-39 is a validated measure of QOL in PD 14 and the scale has 8 subscores (mobility, activities of daily living, emotional, stigma, social, cognition, community, and discomfort). Scores range from 0 to 100 with 100 representing the worst possible function. The Patient Global Impression Scale (PGIS) and the Clinician Global Impression Scale (CGIS) scores (1-very much improved; 2-much improved; 3-minimally improved; 4-no change; 5minimally worse; 6-much worse; 7-very much worse) were also obtained 6 months after DBS. Annual cognitive evaluations [ie, Mini Mental Status Examination (MMSE) and dementia rating scale (DRS)] were also performed.
Surgical Procedure
A high-resolution, volumetric brain magnetic resonance imaging (MRI) was obtained 1 day before surgery followed by a stereotactic head computed tomography (CT) the morning of surgery. CT and MRI image fusion was then performed to map out the neuronal brain structures in coordinate space by software developed at our institution. The brain target point was selected utilizing a combination of direct and indirect targeting. For this series although STN was a target of choice in patients without cognitive issues, GPi was selected when patients had severe "on/off " fluctuations/dyskinesia and testing revealed mild cognitive impairment (dementia rating scale score <130). The anterior commissure, the posterior commissure, and a midline plane were identified to anchor the coordinate system. Multiple-pass microelectrode mapping was employed followed by intraoperative test stimulation to verify lead placement. Moreover, a postoperative CT scan was performed and fused to the MRI to assess lead location. An implantable pulse generator (IPG) was placed approximately 4 weeks after the procedure and DBS programming/medication adjustment was performed by protocol once a month for the first 6 months and then every 3 to 6 months.
Statistical Analysis
Comparisons were made between preoperative and postoperative UPDRS Part III scores in "off" medication states, levodopa equivalent dose, UPDRS Part II, and PDQ-39 values. The Wilcoxon signed rank tests were calculated to assess statistical significance. Statistical analyses were performed utilizing PASW statistics 16.0 (SPSS, Chicago, IL). For patients in the dyskinesia subgroup, the UPDRS Part IV item 32 (duration of dyskinesia) and the preoperative and postoperative dyskinesia rating scale scores 13 were included for comparison. For the medication-refractory tremor subgroup, the UPDRS Part II item 16 (tremor) and Part III item 20 (resting tremor) were compared preoperatively and postoperatively.
RESULTS
Clinical Outcomes
The database search revealed 153 PD DBS patients of which 9 (8 men and 1 woman) with average age of 64.2 met inclusion criteria and had a sub-30% improvement on levodopa/dopaminergic challenge testing. These patients were followed up for at least for 6 months and for an average of 2.5 years. Staged bilateral GPi DBS was performed on the 2 patients with severe dyskinesia who also had mild cognitive impairment (DRS < 130). STN DBS was performed on the remaining patients for dyskinesia (n = 3), "on/off" motor fluctuations (n = 1) and medication-refractory tremor (n = 3). Of 9 patients, 7 patients had staged bilateral DBS. In addition, 2 patients were revealed to have a previous history of pallidotomy, and these patients had unilateral DBS (contralateral to the pallidotomy). The patient characteristics are summarized in Table 1 .
DBS surgery led to a significant improvement in the UPDRS Part III scores at 4 months and 1 year (16% and 12.5% changes, respectively; P < 0.05) ( Table 2) . When followed to last clinical follow-up, statistical significance for change in motor overall motor score was lost, however, target symptoms remained improved. Furthermore, significant improvements (P < 0.05) were observed in the UPDRS Part II and PDQ-39 subscores (ie, activities of daily living, emotional, and stigma) with medium to large effect sizes (Table 3) . Interestingly, the cognition subscore of the PDQ-39 improved in patients who underwent GPi DBS (cases 1 and 2), and no significant deteriorations were observed in MMSE and DRS scores 1 year after the first surgery. Overall improvements were demonstrated by the PGIS and CGIS scores; 5 patients had "very much improved" (score of 1) on both scales, whereas the other 4 had "much improved" (score of 2) on both scales (Table 4 ). Conversely, the statistical analyses failed to detect a significant change in preoperative and postoperative levodopa equivalent dose dosages at 1 year and the last follow-up (P-value > 0.05).
In the dyskinesia subgroup, duration of dyskinesia in waking time decreased in all 5 patients, as did scores on the dyskinesia rating scale ( Table 4 ). The motor fluctuation patient (case 6) preoperatively complained of "off" periods during 50% of a day, however, these periods had completely resolved at 6 months after STN DBS. In the medication-refractory tremor patients, improvements were seen in both items 16 and 20 (Table 4 ).
Complications
Transient mental status change on postoperative day #1 was noted in 2 patients who underwent STN DBS (cases 5 and 7). A transient IPG seroma was encountered in a single patient (case 7). An intracerebral hemorrhage around the STN (12 mm 3 ) resulted in a transient hemiparesis in 1 patient (case 9) that had resolved when the patient returned for the IPG implantation 4 weeks later.
DISCUSSION
The levodopa/dopaminergic challenge test is frequently utilized as the primary first-line screening method to select appropriate DBS candidates with PD. [8] [9] [10] 12 The test has proven particularly useful for excluding parkinsonian syndromes (syndromes deemed not to meet the criteria for idiopathic PD, but may have prominent parkinsonian features), for defining levodopa unresponsive symptoms (eg, gait, balance, speech), and for predicting surgical outcomes. 15 The ability to exclude parkinsonian syndromes has been a particularly important use of the test and a recent study revealed that 5 of 41 referred patients with DBS failure had misdiagnosis due to lack of appropriate challenge testing. 15 Most authorities have promoted that >30% improvement after dopaminergic administration (UPDRS-III testing) may identify the optimal candidates for DBS and those who should move on to a complete interdisciplinary evaluation. Our data however, revealed that at least 3 scenarios exist where alternative indications for DBS might be useful: severe dyskinesia, "on/off" motor fluctuations, and medication-refractory tremor. 3, 5, 6, 16 Anecdotally, many expert centers have observed similar positive results to those reported here (author personal communications with National Parkinson Foundation and other Centers of Excellence for DBS therapy).
There are several important issues that emerge upon closer inspection of the levodopa/dopaminergic challenge test when utilized for screening potential DBS candidates. First, some patients may not tolerate clinically effective doses of levodopa due to complications such as nausea, sedation, and/or dyskinesia, and thus it may be difficult to glean clean data from a levodopa/dopaminergic challenge test. 17, 18 In some cases, severe dyskinesias can impair the performance on select items of the UPDRS such as finger tapping, hand movement, and rapid alternating movements, giving the impression of minimal improvements in these items as highlighted in case 7. In these patients, select examples of successful improvement of symptoms as a result of DBS have been previously reported. 17, 18 In addition, delayed gastric emptying may profoundly impact the measured response of a levodopa/dopaminergic challenge test, 19 and some authors advocate apomorphine as a reasonable alternative in this scenario. 11 Further, another scenario that must be considered is a history of successful lesioning therapy (pallidotomy, thalamotomy, subthalamotomy) that may reduce the measured responsiveness of levodopa and other dopaminergics and ultimately reset the UPDRS off score to a lower (better) baseline. This particular scenario is highlighted in 2 of our reported cases (5 and 9), where previous pallidotomy may have contributed to the sub-30% responsiveness to levodopa/ dopaminergic challenge testing. Moreover, clinicians should be aware that a UPDRS "on/off" test does not reveal the extent or severity of "on/off" motor fluctuations which ultimately require careful history taking and/or formal documentation by a diary. [20] [21] [22] Finally, the threshold values for the levodopa/ dopaminergic challenge test have not been standardized for DBS; values vary in the literature from 25% to 50% in published surgical series. 4, 8, 9, 11, 23, 24 Clinicians should be aware that higher threshold levels on levodopa/dopaminergic challenge testing may lead to excluding potentially reasonable DBS candidates, especially those with dyskinesias, fluctuations, and tremor. In our series, significant improvements were evidenced in the UPDRS Part II (activity of daily living) and in the PDQ-39 QOL subscores despite only subtle improvement in total motor scores, highlighting the importance of not overvaluing UPDRS motor scores. These findings further support the argument that DBS teams should remain vigilant for potential candidates that may not meet the 30% motoric improvement criteria. A recent meta-analysis of STN DBS outcomes revealed 52% improvement in the UPDRS Part III motor section after surgery. 4 The UPDRS motor scores improved by only 16% and 12.5% at 4-month follow-up, respectively, in our series. These improvements may on the surface seem disappointing; however, these improvements failed to measure changes important for an individual patient, as the target symptoms were successfully addressed in each case (Table 4 ) and the improvement contributed to enhanced activity of daily living and QOL scores. The low motor improvement seen in several of our cases is in direct support of the notion that DBS has its effects on levodopa responsive motor symptoms, but that UPDRS III may not tell the whole story. PGIS and CGIS scores also support the observed improvements in our cohort.
Dyskinesia and "on/off" motor fluctuations represent most of the motor complications encountered with long-term levodopa therapy; however, these issues are potentially amenable to DBS therapy. Levodopa dosage and DBS unresponsive PD features (eg, gait, balance, speech) have been demonstrated in recent studies to progress over time, whereas improvements in dyskinesia and "on/off" motor fluctuations seem to persist up to 5 years after STN DBS. 5, 25 Further, a meta-analysis of available studies in the literature revealed 69.1% and 68.2% reduction in dyskinesia and daily off periods after DBS. 4 Thus, those patients with a chief complaint of severe dyskinesia or "on/off" motor fluctuations may have the potential to experience symptomatic improvement from DBS and this improvement may translate into improved activities of daily living, QOL, and global outcome scores. This improvement may be evident even when significant improvement in UPDRS motor scores is absent.
The issue of preexisting cognitive dysfunction has led many groups to shy away from DBS implantation primarily because of fear of worsening deficits. 26 Typically DRS scores of 130 or above are considered to be the minimal cut-off for DBS surgery. 8 Some groups have also alternatively used a MMSE score >24 as a selection criteria to exclude frank dementia. 6 Interestingly, in our series, 2 patients had temporary mental status change after STN DBS, whereas the 2 patients with preexisting mild cognitive impairment seemed to tolerate the GPi target without worsening of the cognitive status. Although clearly more data are needed, recent studies have revealed the possibility that the incidence of cognitive adverse events may be lower with GPi DBS when compared with STN DBS. 1, 7, 27, 28 GPi DBS has been shown to be a powerful direct suppressor of dyskinesia and also is effective against "on/off" motor fluctuations. 1, 3, 27 In this small series, we utilized the GPi option for preexisting cognitive dysfunction. It should be noted, however, that we did not attempt STN DBS, and thus we cannot comment on the superiority of one approach over another.
DBS has been recommended for advanced PD patients by the Core Assessment Program for Surgical Interventional Therapies in Parkinson's Disease. This committee also recommended selecting patients with at least a 5-year disease duration. 8 However, in our cohort 2 patients had disabling tremor despite relatively short disease durations (cases 7 and 8) and both benefitted from STN DBS. STN DBS may thus be a reasonable treatment option for medication-refractory tremor in earlier stage PD. Although ventral intermediate thalamic nucleus (Vim) is also a viable target for medically-refractory tremor, Vim DBS does not as effectively address other cardinal symptoms of PD or address the development of lower extremity tremor. 29 Fraix et al 29 reported favorable results when utilizing bilateral or contralateral STN DBS after thalamic surgery for tremor dominant PD patients. The relative roles of STN, GPi, and thalamic DBS in medication-refractory tremor have not been carefully analyzed in randomized controlled trials and currently most groups are choosing the STN as the target unless cognitive dysfunction is present. Further study is needed in this area.
The data from our cohort demonstrates benefit in wellselected PD patients with a preoperative sub-30% UPDRS motor change if the diagnosis of PD is a reasonable certainty. We would and therefore do argue that DBS indications should be tailored to the individual patient, and that the indications for surgery should be given strong weight in an interdisciplinary evaluation for selection of appropriate patients. Patients with severe dyskinesia, "on/off" fluctuations, and/or medicationrefractory tremor may thus be reasonable DBS candidates even if they fail a classic levodopa/dopaminergic challenge test. Although this case series suffers from biases introduced by its retrospective and unblinded nature and the limited number of observations, we feel the data tell an important story. Further studies should be pursued to confirm these findings. In the meantime, we would encourage groups to employ an interdisciplinary screening process for DBS indications that tailors decisions to the individual patient, even if the results of a levodopa/dopaminergic challenge test fall short of widely accepted criteria.
